
PURE Bioscience Unveils Revolutionary Membrane Treatment Solution for the Dairy and Beverage Industry
EL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) ('PURE,' the 'Company' or 'we'), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, is proud to announce an innovative application method for membrane treatment in the dairy and beverage industry using our flagship product, PURE® Hard Surface. This groundbreaking solution addresses common membrane fouling and sanitization challenges, delivering outstanding results that enable operators to restore throughput and sanitize the membrane without damage or oxidation.
This groundbreaking solution addresses common membrane fouling and sanitization challenges, delivering outstanding results that enable operators to restore throughput and sanitize the membrane without damage or oxidation.
Tom Myers, EVP of Technology & Development at PURE Bioscience, stated, 'The introduction of PURE Hard Surface to the Dairy and Beverage industry represents a significant advancement in membrane treatment technology. This product delivers unmatched efficiency and enhances filtration operation and longevity.'
Key Attributes of PURE Hard Surface for Membrane Treatment:
One Treatment—Zero Compromises: Achieve superior results with just one treatment. PURE Hard Surface effectively removes fouling, restores flow, and delays the need for membrane replacement without compromising membrane integrity.
Proven Performance: Our solution boasts results with successful treatments demonstrating an impressive 4+ log reduction in 120 seconds. Additionally, it is NSF-listed, making it ideal for eliminating harmful bacteria in the dairy industry without causing membrane oxidation.
Complete Penetration in Minutes: In practical applications, our treatment has shown complete membrane penetration within 5 minutes for reverse osmosis (RO) systems, effectively scrubbing away fouling and restoring throughput. Similarly, our ultrafiltration treatment (UF) systems resulted in immediate penetration and unmatched restoration of throughput while sanitizing to meet stringent quality specifications.
Simplicity and Effectiveness: Membrane operators prefer PURE Hard Surface for its no-hassle approach. The ready-to-use formula requires no mixing—fill and go. Plus, with the lowest EPA toxicity rating, there is no need for personal protective equipment, making it highly safe for staff.
Environmentally Safe: Our treatment poses no risks to wastewater systems, ensuring no impact on digesters or discharge permit compliance.
Cost-Effective Solution: With just one treatment, manufacturers can sell full-priced finished goods, reduce operational costs, and significantly prolong the lifespan of their membranes, contributing to overall operational efficiency.
'Our SDC technology is redefining what's possible in the food industry – and PURE Hard Surface is at the forefront,' said Tim Steffensmeier, Vice President of Sales. 'This modern membrane application brings a smarter, more efficient approach to streamlining operation, delivering a measurable cost savings, and empowers manufacturers to uphold the highest quality standards in the industry, without the negative trade-offs of traditional chemistry.'
Discover the transformative benefits of PURE Hard Surface for membrane treatment. For more information, visit www.purebio.com/membrane, contact one of our key distributors, or come to our booth at the Dairy Foods Membrane Technology Forum, June 2-4, 20025 in Bloomington, MN.
How SDC Works
SDC kills microorganisms by two modes of action: 1) the silver ion deactivates structural and metabolic membrane proteins, leading to microbial death; 2) the microbes view SDC as a food source, allowing the silver ion to enter the microbe. Once inside the organism, the silver ion denatures the DNA, which halts the microbe's ability to replicate and leads to its death. This dual action makes SDC highly and quickly effective against a broad spectrum of microbes. Traditional silver-based disinfectants have short shelf lives – from hours to days. SDC is a stabilized silver ion complex with a shelf life of several years. The unique bond between the silver ions in SDC allows them to remain in solution while making them more bioavailable for antimicrobial action.
About PURE Bioscience, Inc.
PURE focuses on developing and commercializing our proprietary antimicrobial products, primarily in food safety. We provide best-in-class solutions to combat the health and environmental challenges of pathogens and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This broad-spectrum, non-toxic antimicrobial agent formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, and mitigation of bacterial resistance. PURE's mailing address is 771 Jamacha Rd. #512, El Cajon, California 92019 (San Diego County area), which serves as its official address for all business requirements.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Confused by latest order? How to calculate if your Jackson County assessment is within limits
KANSAS CITY, Mo. — Jackson County assessments are showing up in homeowner's mailboxes. Some people may be surprised at the increase after a May order from the State Tax Commission. Some taxpayers may receive tax refunds in June: When payments could arrive That order capped increases in each assessment period at 15% and set 2022 as a starting point for this year's assessments after 2023 assessments were heavily contested. But determining your maximum 2025 assessment is a little bit more complicated than a single multiplication or division. Legislator Sean Smith and Preston Smith (no relation) have been helping homeowners with appeals since assessments skyrocketed in 2023. This week as they went out again they've been getting questions about what the latest State Tax Commission Order and 15% cap really means. 'People look at it and the first thing they see is, I thought it was only going to be a 15% increase and that was the perception. I've probably answered it online 100 times,' Preston Smith said. 'A lot of people are contacting me thinking they only do the 15 percent once, but you have to do it twice,' Legislator Sean Smith explained. To illustrate how it works with the latest rules using 2022 assessments as the starting point, consider a home with a $100,000 assessed value in 2022. To calculate the maximum assessed value in 2023 multiply $100,000 by 1.15 which is $115,000. But then you have to multiply by 115% again to determine the maximum value a home could be assessed at this year. In this example it would be $132,250. The two 15% increases end up yielding a maximum increase of 32.25% during the two assessment periods. 'I would really urge people to do the math themselves to check it, check and really verify,' Preston Smith said. To do that, however, you have to know your home's 2022 assessed value, which according to those who have received this year's assessments, isn't on this year's notices. You can find that historical information online at the Jackson County Parcel Viewer or Ascend Web. If your increase ends up beyond the allowances under the State order or if you simply don't agree with your value, you still can appeal. Appeals have to be filed by July 14. Download WDAF+ for Roku, Fire TV, Apple TV As for seniors, 40,000 are already enrolled in a new tax credit program freezing tax bills. The county says estimated savings are included on notices, but are subject to change. Both Sean and Preston Smith say they are pressing the Assessor's Office for complete assessment data in 2022, 2023 and 2025 to see how much home values increased, and how many of those increases equated to the maximum allowed if no new construction was done under the State Tax Commission Order without a physical inspection. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
9 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
9 hours ago
- Yahoo
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.